Impact of nucleic acid testing for human immunodeficiency virus and hepatitis C virus on blood product availability, outdating, and patient safety: Results of the 2001 AABB/CAP Viral Marker C survey

Archives of Pathology and Laboratory Medicine

Volumn 126, Issue 12, 2002, Pages 1463-1466

  Sherman, Laurence A ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEIC ACID;

ARTICLE; BLOOD DONOR; BLOOD STORAGE; ERYTHROCYTE; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; INFECTION CONTROL; INFECTION RISK; MAJOR CLINICAL STUDY; THROMBOCYTE;

BLOOD BANKS; DNA, VIRAL; HEPACIVIRUS; HIV; HUMANS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; RNA, VIRAL; SAFETY; VIREMIA;

EID: 0037000737     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. College of American Pathologists Surveys 2001. VM-C AABB/CAP Viral Markers: Participant Summary Report. Northfield, III: College of American Pathologists; 2001.
2. Tabor E, Yu M-YW, Hewlett I, Epstein JS. Summary of a workshop on the implementation of NAT to screen donors of blood and plasma for viruses. Transfusion. 2000;40:1273-1275.
3. Stramer S, Cagliotti S, Strong DM. NAT of the United States and Canadian blood supply. Transfusion. 2000;40:1165-1168.
4. Sherman LA. Residues of NAT: questions and commentary. Transfusion. 2000;40:1268-1272.
5. Busch MP, Dodd RY. NAT and blood safety: what is the paradigm? Transfusion. 2000;40:1157-1160.
6. 2000-2001 Directory of Community Blood Centers. Bethesda, Md: American Association of Blood Centers; 2001.